Stoke Therapeutics, Inc. (STOK) FY2025 10-K Annual Report
Stoke Therapeutics, Inc. (STOK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 16, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Stoke Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: RNA-based medicines using proprietary TANGO platform to upregulate protein expression for treating severe genetic diseases
- • New focus: Phase 3 study of zorevunersen for Dravet syndrome initiated May 2025, plus Phase 1 study of STK-002 for autosomal dominant optic atrophy
Management Discussion & Analysis
- • Revenue $184.4M in 2025 vs $36.6M in 2024, up $147.8M mainly from Biogen collaboration ($168.3M in 2025) offset by Acadia decline
- • Net loss $6.9M in 2025 vs $89.0M in 2024; operating loss improved to $20.6M from $101.4M; operating margin approx. -11.2% vs -277.1%
Risk Factors
- • Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development
- • Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations
Stoke Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$184M
▲ +404.5% YoY
Net Income
-$7M
▲ +92.3% YoY
Operating Margin
-11.2%
▲ +26615bp YoY
Net Margin
-3.7%
▲ +23968bp YoY
ROE
-2.0%
▲ +3690bp YoY
Total Assets
$418M
▲ +54.1% YoY
EPS (Diluted)
$-0.12
▲ +92.7% YoY
Operating Cash Flow
$46M
▲ +152.5% YoY
Source: XBRL data from Stoke Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Stoke Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.